Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma

Ho Jin Shin, Won Sik Lee, Ho Seop Lee, Hawk Kim, Gyeong Won Lee, Moo Kon Song, Jinseok Kim, Ho Young Yhim, Joo Seop Chung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3% vs. 15.0%) and overall survival (OS) (70.2% vs. 42.0%) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.

Original languageEnglish
Pages (from-to)2490-2496
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number11
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Busulfan
Lymphoma, Large B-Cell, Diffuse
Stem Cells
Transplants
Carmustine
Melphalan
Survival
Cytarabine
Etoposide
Cyclophosphamide
Conditioning (Psychology)
Survival Rate
Mortality
Rituximab

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Shin, Ho Jin ; Lee, Won Sik ; Lee, Ho Seop ; Kim, Hawk ; Lee, Gyeong Won ; Song, Moo Kon ; Kim, Jinseok ; Yhim, Ho Young ; Chung, Joo Seop. / Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 11. pp. 2490-2496.
@article{c48aea4490504b978f4628ee253a04d5,
title = "Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma",
abstract = "We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3{\%} vs. 15.0{\%}) and overall survival (OS) (70.2{\%} vs. 42.0{\%}) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.",
author = "Shin, {Ho Jin} and Lee, {Won Sik} and Lee, {Ho Seop} and Hawk Kim and Lee, {Gyeong Won} and Song, {Moo Kon} and Jinseok Kim and Yhim, {Ho Young} and Chung, {Joo Seop}",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.882504",
language = "English",
volume = "55",
pages = "2490--2496",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. / Shin, Ho Jin; Lee, Won Sik; Lee, Ho Seop; Kim, Hawk; Lee, Gyeong Won; Song, Moo Kon; Kim, Jinseok; Yhim, Ho Young; Chung, Joo Seop.

In: Leukemia and Lymphoma, Vol. 55, No. 11, 01.01.2014, p. 2490-2496.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma

AU - Shin, Ho Jin

AU - Lee, Won Sik

AU - Lee, Ho Seop

AU - Kim, Hawk

AU - Lee, Gyeong Won

AU - Song, Moo Kon

AU - Kim, Jinseok

AU - Yhim, Ho Young

AU - Chung, Joo Seop

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3% vs. 15.0%) and overall survival (OS) (70.2% vs. 42.0%) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.

AB - We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3% vs. 15.0%) and overall survival (OS) (70.2% vs. 42.0%) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.

UR - http://www.scopus.com/inward/record.url?scp=84912111705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912111705&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.882504

DO - 10.3109/10428194.2014.882504

M3 - Article

C2 - 24432893

AN - SCOPUS:84912111705

VL - 55

SP - 2490

EP - 2496

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -